Sangamo Therapeutics Inc (NASDAQ:SGMO)’s traded shares stood at 4.27 million during the last session, with the company’s beta value hitting 1.29.The SGMO share’s 52-week high remains $3.18, putting it -189.09% down since that peak but still an impressive 72.73% since price per share fell to its 52-week low of $0.30. The company has a valuation of $229.51M, with an average of 7.97 million shares in intraday trading volume over the past 10 days and average of 10.45 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Sangamo Therapeutics Inc (SGMO), translating to a mean rating of 1.88. Of 3 analyst(s) looking at the stock, 0 analyst(s) give SGMO a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
The 5-day price performance for the stock is -9.47%, and -46.34% over 30 days. With these gigs, the year-to-date price performance is 7.84%. Short interest in Sangamo Therapeutics Inc (NASDAQ:SGMO) saw shorts transact 21.52 million shares and set a 2.26 days time to cover.
The extremes give us $2 and $3 for target low and target high price respectively. As such, SGMO has been trading -172.73% off suggested target high and -81.82% from its likely low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Looking at statistics comparing Sangamo Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Sangamo Therapeutics Inc (SGMO) shares are 152.29% up over the last 6 months, with its year-to-date growth rate higher than industry average at 20.34% against 16.70%. The rating firms project that company’s revenue will shrink -65.51% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 10.32M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 31.5M.Earnings reports from the last fiscal year show that sales brought in 2.04M and 481k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 405.22% before jumping 6,448.86% in the following quarter.
SGMO Dividends
Sangamo Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Sangamo Therapeutics Inc insiders hold 2.36% of total outstanding shares, with institutional holders owning 24.33% of the shares at 24.92% float percentage. In total, 24.33% institutions holds shares in the company, led by WASATCH ADVISORS LP. As of 2024-06-30, the company held over 20.09 million shares (or 11.1403% of shares), all amounting to roughly $7.2 million.
The next major institution holding the largest number of shares is ARMISTICE CAPITAL, LLC with 14.06 million shares, or about 7.7963% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $5.04 million.
We also have Wasatch Ultra Growth Fund and Wasatch Microcap Fund as the top two Mutual Funds with the largest holdings of the Sangamo Therapeutics Inc (SGMO) shares. Going by data provided on Sep 30, 2024 , Wasatch Ultra Growth Fund holds roughly 10.97 shares. This is just over 5.26% of the total shares, with a market valuation of $12.07 million. Data from the same date shows that the other fund manager holds a little less at 5.65, or 2.71% of the shares, all valued at about 6.21 million.
